Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis | 12 | 2023 | 2029 | 1.270 |
Why?
|
Antitubercular Agents | 11 | 2023 | 1397 | 1.150 |
Why?
|
HIV Infections | 34 | 2024 | 17589 | 0.950 |
Why?
|
Isoniazid | 11 | 2023 | 288 | 0.880 |
Why?
|
Latent Tuberculosis | 4 | 2024 | 224 | 0.610 |
Why?
|
Tuberculosis, Multidrug-Resistant | 2 | 2018 | 944 | 0.410 |
Why?
|
Anti-HIV Agents | 7 | 2022 | 4576 | 0.330 |
Why?
|
Research Design | 3 | 2020 | 6213 | 0.320 |
Why?
|
Models, Biological | 2 | 2023 | 9499 | 0.300 |
Why?
|
Models, Statistical | 1 | 2020 | 5107 | 0.260 |
Why?
|
Tuberculosis, Pulmonary | 3 | 2016 | 843 | 0.220 |
Why?
|
Pharmacology | 1 | 2021 | 97 | 0.190 |
Why?
|
Patient Compliance | 5 | 2011 | 2701 | 0.190 |
Why?
|
Pregnancy Outcome | 3 | 2021 | 2957 | 0.190 |
Why?
|
Antiretroviral Therapy, Highly Active | 5 | 2016 | 1903 | 0.190 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 10397 | 0.180 |
Why?
|
Anti-Retroviral Agents | 6 | 2022 | 1794 | 0.170 |
Why?
|
Sample Size | 1 | 2023 | 848 | 0.170 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2024 | 2183 | 0.170 |
Why?
|
Immunity, Humoral | 1 | 2024 | 610 | 0.170 |
Why?
|
Pregnant Women | 2 | 2022 | 571 | 0.170 |
Why?
|
Alkynes | 1 | 2020 | 327 | 0.170 |
Why?
|
Pregnancy | 13 | 2024 | 30175 | 0.160 |
Why?
|
Cyclopropanes | 1 | 2020 | 437 | 0.160 |
Why?
|
Benzoxazines | 1 | 2020 | 321 | 0.160 |
Why?
|
Child | 26 | 2023 | 80969 | 0.160 |
Why?
|
Antibodies, Bacterial | 1 | 2024 | 1478 | 0.150 |
Why?
|
Vitamin D Deficiency | 2 | 2019 | 1388 | 0.150 |
Why?
|
Muscular Diseases | 1 | 2022 | 555 | 0.150 |
Why?
|
Infant | 14 | 2024 | 36541 | 0.140 |
Why?
|
Statistics as Topic | 2 | 2021 | 2359 | 0.140 |
Why?
|
Postpartum Period | 3 | 2023 | 1198 | 0.130 |
Why?
|
Medication Adherence | 3 | 2013 | 2192 | 0.130 |
Why?
|
Plakophilins | 1 | 2016 | 32 | 0.130 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2019 | 664 | 0.130 |
Why?
|
Hepatitis B | 1 | 2020 | 711 | 0.120 |
Why?
|
Mycobacterium tuberculosis | 2 | 2024 | 1930 | 0.110 |
Why?
|
Viral Load | 5 | 2016 | 3398 | 0.110 |
Why?
|
Vitamin D | 2 | 2019 | 3311 | 0.110 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8055 | 0.110 |
Why?
|
Adolescent Behavior | 2 | 2012 | 1190 | 0.100 |
Why?
|
Behavior | 1 | 2016 | 543 | 0.100 |
Why?
|
Lymphocyte Count | 1 | 2015 | 793 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2017 | 773 | 0.100 |
Why?
|
BCG Vaccine | 2 | 2024 | 383 | 0.090 |
Why?
|
South Africa | 3 | 2023 | 1872 | 0.090 |
Why?
|
Humans | 39 | 2024 | 768887 | 0.090 |
Why?
|
Risk Assessment | 3 | 2020 | 24330 | 0.090 |
Why?
|
HIV Protease Inhibitors | 1 | 2012 | 432 | 0.080 |
Why?
|
Social Responsibility | 2 | 2012 | 384 | 0.080 |
Why?
|
Female | 31 | 2024 | 397464 | 0.080 |
Why?
|
Adolescent Development | 2 | 2009 | 282 | 0.080 |
Why?
|
Central Nervous System Stimulants | 2 | 2016 | 1182 | 0.080 |
Why?
|
Primary Prevention | 1 | 2016 | 1187 | 0.080 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2020 | 1360 | 0.080 |
Why?
|
Cytomegalovirus Infections | 1 | 2015 | 839 | 0.080 |
Why?
|
Adolescent | 20 | 2021 | 89247 | 0.080 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2022 | 622 | 0.080 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2714 | 0.070 |
Why?
|
Child, Preschool | 13 | 2022 | 42684 | 0.070 |
Why?
|
Computer Simulation | 1 | 2021 | 6289 | 0.070 |
Why?
|
Central Nervous System Diseases | 1 | 2012 | 521 | 0.070 |
Why?
|
T-Lymphocyte Subsets | 1 | 2015 | 1813 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2016 | 1673 | 0.070 |
Why?
|
Child Behavior | 1 | 2012 | 865 | 0.070 |
Why?
|
Child Behavior Disorders | 1 | 2011 | 813 | 0.060 |
Why?
|
Caregivers | 3 | 2013 | 2308 | 0.060 |
Why?
|
CD4 Lymphocyte Count | 2 | 2016 | 2598 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 2008 | 752 | 0.060 |
Why?
|
Longitudinal Studies | 7 | 2019 | 14795 | 0.060 |
Why?
|
Africa, Southern | 1 | 2023 | 60 | 0.060 |
Why?
|
Infant, Newborn | 5 | 2024 | 26394 | 0.050 |
Why?
|
Adult | 9 | 2024 | 223818 | 0.050 |
Why?
|
Carnitine | 1 | 2022 | 253 | 0.050 |
Why?
|
Tuberculin Test | 1 | 2021 | 205 | 0.050 |
Why?
|
Child Development | 2 | 2009 | 2337 | 0.050 |
Why?
|
Parents | 2 | 2012 | 3597 | 0.040 |
Why?
|
Arylamine N-Acetyltransferase | 1 | 2020 | 87 | 0.040 |
Why?
|
Metabolic Clearance Rate | 1 | 2020 | 363 | 0.040 |
Why?
|
Young Adult | 9 | 2020 | 60110 | 0.040 |
Why?
|
Rifampin | 1 | 2022 | 351 | 0.040 |
Why?
|
Male | 20 | 2024 | 365249 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2020 | 65485 | 0.040 |
Why?
|
Body Weight | 3 | 2020 | 4628 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2016 | 7885 | 0.040 |
Why?
|
Cost of Illness | 1 | 2008 | 1959 | 0.040 |
Why?
|
Viremia | 1 | 2021 | 725 | 0.040 |
Why?
|
Cognition | 1 | 2016 | 7080 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2019 | 526 | 0.040 |
Why?
|
Family | 1 | 2008 | 3208 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 4053 | 0.040 |
Why?
|
Hepatitis B virus | 1 | 2020 | 533 | 0.030 |
Why?
|
Infant, Very Low Birth Weight | 1 | 2019 | 408 | 0.030 |
Why?
|
Peru | 1 | 2019 | 891 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2022 | 2226 | 0.030 |
Why?
|
Antipsychotic Agents | 1 | 2009 | 3081 | 0.030 |
Why?
|
Drug Interactions | 1 | 2020 | 1421 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2020 | 12469 | 0.030 |
Why?
|
Phospholipid Transfer Proteins | 1 | 2016 | 90 | 0.030 |
Why?
|
Receptors, Interleukin-1 | 1 | 2016 | 260 | 0.030 |
Why?
|
Vitamin D-Binding Protein | 1 | 2016 | 130 | 0.030 |
Why?
|
Infant Mortality | 1 | 2019 | 751 | 0.030 |
Why?
|
Cognition Disorders | 1 | 2008 | 3985 | 0.030 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2009 | 3743 | 0.030 |
Why?
|
Quality of Life | 1 | 2016 | 13510 | 0.030 |
Why?
|
HIV | 1 | 2021 | 1596 | 0.030 |
Why?
|
DNA, Viral | 1 | 2020 | 2205 | 0.030 |
Why?
|
Receptors, Calcitriol | 1 | 2016 | 361 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39394 | 0.030 |
Why?
|
Body Height | 2 | 2009 | 1568 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2021 | 3163 | 0.030 |
Why?
|
Phylogeny | 1 | 2020 | 2843 | 0.030 |
Why?
|
Prospective Studies | 4 | 2020 | 54950 | 0.030 |
Why?
|
Prevalence | 2 | 2023 | 15875 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2727 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2022 | 6320 | 0.020 |
Why?
|
Body Mass Index | 1 | 2009 | 13054 | 0.020 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2024 | 2541 | 0.020 |
Why?
|
Wechsler Scales | 1 | 2012 | 258 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2016 | 1195 | 0.020 |
Why?
|
Bacteriological Techniques | 1 | 2012 | 277 | 0.020 |
Why?
|
California | 1 | 2015 | 1443 | 0.020 |
Why?
|
Internal-External Control | 1 | 2012 | 350 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2015 | 1866 | 0.020 |
Why?
|
Mental Disorders | 1 | 2009 | 6879 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2015 | 1560 | 0.020 |
Why?
|
Reference Standards | 1 | 2012 | 1014 | 0.020 |
Why?
|
Age Factors | 2 | 2016 | 18454 | 0.020 |
Why?
|
HIV Seropositivity | 1 | 2013 | 967 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2019 | 22294 | 0.020 |
Why?
|
Premature Birth | 1 | 2019 | 1814 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2012 | 7148 | 0.020 |
Why?
|
Intelligence Tests | 1 | 2008 | 505 | 0.020 |
Why?
|
Genetic Variation | 1 | 2022 | 6610 | 0.020 |
Why?
|
HLA Antigens | 1 | 2012 | 1336 | 0.020 |
Why?
|
Self Care | 1 | 2012 | 801 | 0.020 |
Why?
|
Time Factors | 3 | 2016 | 40266 | 0.020 |
Why?
|
Genotype | 1 | 2020 | 13048 | 0.020 |
Why?
|
United States | 3 | 2023 | 73180 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2597 | 0.020 |
Why?
|
Risk Factors | 3 | 2019 | 74971 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2017 | 3858 | 0.010 |
Why?
|
Antigens, CD | 1 | 2015 | 4032 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4862 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2015 | 5505 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10115 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7602 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2022 | 81892 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2012 | 2339 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 21545 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2009 | 6242 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2008 | 2742 | 0.010 |
Why?
|
Cohort Studies | 2 | 2016 | 41800 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2012 | 4413 | 0.010 |
Why?
|
Linear Models | 1 | 2009 | 5890 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2012 | 4651 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2012 | 26384 | 0.010 |
Why?
|
RNA, Viral | 1 | 2005 | 2871 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2005 | 2203 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 16051 | 0.010 |
Why?
|
Middle Aged | 2 | 2020 | 223740 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2008 | 12093 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 18065 | 0.010 |
Why?
|
HIV-1 | 1 | 2009 | 6963 | 0.010 |
Why?
|
Logistic Models | 1 | 2006 | 13317 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15955 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2008 | 20244 | 0.010 |
Why?
|
Concepts
(167)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(20)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_